Dexin Medical Successfully Hosts 2024 South China Distributor Conference in Guangzhou, Showcasing Innovative Structural Heart Solutions
Valgen Medtech
Minimally Invasive Interventional Device Developer
On August 9, 2024, Valgen Medtech's South China Distributor Conference kicked off in Guangzhou, attracting numerous potential partners to gather, jointly explore new cooperation opportunities, and embark on a new chapter of development together.
Mr. Li Pei, Vice General Manager of Valgen Medtech
Meeting Venue
At the beginning of the meeting, Mr. Li Pei, Vice General Manager of Valgen Medtech, delivered an opening speech, warmly and sincerely welcoming each guest and elaborating on the profound impact and extraordinary value of this conference for Valgen Medtech's business expansion.
Mr. Yin Ye, Business Channel Manager of Valgen Medtech
Ms. Chen Hong, Technical Support Engineer at Valgen Medtech
Ms. Qian Qi, Product Manager of Valgen Medtech
The atmosphere during the live discussion and Q&A session was enthusiastic, with participants actively asking questions. The Valgen Medtech team provided detailed and satisfactory answers to core topics such as business policy details, product features, and market prospects, leveraging their professional knowledge and extensive experience for their dealer partners.
The South China Distributors Conference is not only a "bridge" for communication between Valgen Medtech and potential partners, but also a new starting point for both parties to plan for future development. In the future, Valgen Medtech will continue to expand, embrace more cooperation opportunities, and contribute to the advancement of the medical industry.
Valgen Medtech Co., Ltd. was founded in 2015 and focuses on interventional treatment products and technologies for mitral and tricuspid valve diseases. The company has applied for over 500 patents globally, with more than 180 already authorized. Four innovative products independently developed by the company have passed the special review process for innovative medical devices by the pharmaceutical regulatory authority. Its range of interventional treatment devices, represented by the Dragon series, will greatly enrich clinical options in China for treating structural heart disease.
Core Product DragonFly™ Transcatheter Mitral Valve Clip System – As the first China-developed transvenous edge-to-edge repair product in China, it has been approved by the NMPA for official launch in China. The product is supported by the national "14th Five-Year Plan" key research and development program. In addition, other currently marketed products include Sister Pu™ Medical Radiation Protection Screen and Magpie™ Balloon Dilation Catheter.DragonPath™ Transseptal System, and a series of guidewires, among other products.